Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
This study, called CHOROS, is looking back at information gathered from a number of different, ongoing studies. It focuses on how an inhaler called Budesonide/Glycopyrronium/Formoterol (BGF) is used by people with a lung condition called Chronic Obstructive Pulmonary Disease (COPD). The aim is to understand how well this treatment works and is used in everyday doctor's surgeries and clinics. This is not a new experiment, but rather a look at existing data from studies in various countries, including the UK. It could help doctors understand more about treating COPD with this particular inhaler in real-world situations.
At a glance
What is this study about?
Imagine doctors want to understand how a particular asthma and COPD inhaler, called Budesonide/Glycopyrronium/Formoterol (BGF), works when people use it in their daily lives, outside of a strict research environment. This study, named CHOROS, is doing exactly that. Instead of setting up new trials, it's gathering and analysing existing information from several ongoing studies that are already happening in different countries, including the UK.
These ongoing studies have been collecting information from patients with a lung condition called Chronic Obstructive Pulmonary Disease (COPD) who have started taking the BGF inhaler. By bringing all this information together, researchers hope to get a clearer picture of how the inhaler is being used and its effects in a wide range of real-world situations, rather than in highly controlled research settings. This type of research is important because it reflects what actually happens in doctors' offices and clinics.
Ultimately, the goal is to learn more about how this specific treatment works for people with COPD in their everyday healthcare. This information can then help doctors make better decisions about treating COPD in the future. It's about using existing medical records and data to improve our understanding of treatments in a practical way.
Key takeaways
- This study looks at how a specific inhaler (BGF) works for people with COPD in real-life settings.
- It uses medical information from ongoing studies, not new experiments.
- The aim is to understand the treatment better for future patient care.
- You don't need to do anything extra; it's about using existing, consented data.
- Your personal details are kept private and secure.
- There are no direct risks or benefits to you from this specific data analysis.
Who may be eligible?
For your information to be included in this study, you would need to have Chronic Obstructive Pulmonary Disease (COPD).
Also, your doctor must have decided to start you on the Budesonide/Glycopyrronium/Formoterol (BGF) inhaler based on current guidelines and their medical judgment. Your information would only be included if you are already part of one of the ongoing studies that are providing data for this analysis.
Crucially, you would have needed to give your clear permission for your medical information from that ongoing study to be used for this kind of further research.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Do I have Chronic Obstructive Pulmonary Disease (COPD)?
- Did my doctor prescribe the BGF inhaler for my COPD?
- Am I currently taking part in another ongoing clinical study for COPD?
- Have I given permission for my medical information from that study to be used for further research?
What does participation involve?
This is a study that looks at existing information, not a new trial where you would try a new medicine or follow a specific plan. If your information is included, it means you are already part of a separate, ongoing study where you're receiving your usual care for COPD, including the BGF inhaler. Your participation is simply that your data, which you've already agreed to share from that ongoing study, will be added to a larger collection of similar information.
You wouldn't have any extra visits, assessments, or medications specifically for this CHOROS study. It's all about using information that has already been collected during your routine medical care and consented to for research. There's no new follow-up required from your side for this particular analysis, and no total duration of participation other than the duration of the original study you're in.
Potential risks and benefits
Locations (7)
- Research SiteVerified postcodeMississauga, Canada· Not yet recruiting
- Research SiteVerified postcodeHamburg, Germany· Recruiting
- Research SiteVerified postcodeAthens, Greece· Recruiting
- Research SiteVerified postcodeMilan, Italy· Recruiting
- Research SiteVerified postcodeTokyo, Japan· Recruiting
- Research SiteVerified postcodeBucharest, Romania· Not yet recruiting
- Research SiteVerified postcodeLondon, United Kingdom· Recruiting
Common questions
What is COPD?
COPD stands for Chronic Obstructive Pulmonary Disease, a common lung condition that causes breathing difficulties.
What is BGF?
BGF is a type of inhaler that contains three medicines and is used to treat lung conditions like COPD.
Am I part of this study?
If you are not currently in an ongoing clinical study for COPD, then your information is not likely to be included in this particular analysis.
Will this study affect my treatment?
No, this study uses existing data and will not change your current treatment plan or medical care.
Is my personal information safe?
Yes, your personal details are kept private. The study uses anonymised information, meaning it can't be linked back to you personally.
How to find out more
AstraZeneca Clinical Study Information Center
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.